This database contains 1058 studies, archived under the term: "aged"
Click here to filter this large number of results.
Keeping up health promotion practices in specialized day care units for people with dementia
Background: Health promotion practices hold promises for elderly individuals’ quality of life. This article shows that such practices can be promoted in specialized day care units for individuals with dementia.; Method: Group interviews with 8 groups of staff (comprising 24 staff members) in 3 day care units.; Results: Rather than referring directly to health promotion […]
Plasma proteomics for the identification of Alzheimer disease
Less-invasive biomarkers for early Alzheimer disease (AD) are urgently needed. The present study aimed to establish a panel of plasma proteins that accurately distinguishes early AD from physiological aging and to compare the findings with previous reports. Fifty-eight healthy controls (CON) and 109 patients with AD dementia were randomly split into a training (40%) and […]
Evaluating proFamilies-dementia: adopting photovoice to capture clinical significance
Dementia is a challenging chronic illness that affects the patients and their families. Families often perform a full-time, specialised role, which requires expert knowledge and skills. This paper describes the evaluation of proFamilies-dementia (a programme developed to support families that care for a relative with dementia) using an innovative participatory methodology: photovoice, a qualitative method […]
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline
Grundman, Michael,
Pontecorvo, Michael J.,
Salloway, Stephen P.,
Doraiswamy, P. Murali,
Fleisher, Adam S.,
Sadowsky, Carl H.,
Nair, Anil K.,
Siderowf, Andrew,
Lu, Ming,
Arora, Anupa K.,
Agbulos, Abigail,
Flitter, Matthew L.,
Krautkramer, Michael J.,
Sarsour, Khaled,
Skovronsky, Daniel M.,
Mintun, Mark A.
Florbetapir F18 has been approved by the Food and Drug Administration for in vivo assessment of amyloid pathology in patients undergoing evaluation for Alzheimer disease (AD). The aim of this study was to determine the impact of amyloid imaging on the diagnoses and management of patients undergoing evaluation for cognitive decline. Patients were recruited to […]
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease
Grove, Richard A.,
Harrington, Conn M.,
Mahler, Andreas,
Beresford, Isabel,
Maruff, Paul,
Lowy, Martin T.,
Nicholls, Andrew P.,
Boardley, Rebecca L.,
Berges, Alienor C.,
Nathan, Pradeep J.,
Horrigan, Joseph P.
Introduction: Histaminergic H3 receptors may play a role in modulating cholinergic and monoaminergic neurotransmission. This Phase II study evaluated the efficacy and safety of GSK239512, a highly potent, brain penetrant H3 receptor antagonist as monotherapy treatment for subjects with mild-to-moderate probable Alzheimer’s disease (AD).; Methods: In this 16-week, double-blind, randomized, parallel group study, 196 currently […]
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors
Grossberg, George T.,
Manes, Facundo,
Allegri, Ricardo F.,
Gutiérrez-Robledo, Luis Miguel,
Gloger, Sergio,
Xie, Lei,
Jia, X. Daniel,
Pejović, Vojislav,
Miller, Michael L.,
Perhach, James L.,
Graham, Stephen M.
Introduction: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors.; Methods: In this 24-week, double-blind, multinational study (NCT00322153), outpatients with AD (Mini-Mental State Examination scores of […]
Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer’s disease
Grossberg, G.,
Cummings, J.,
Frolich, L.,
Bellelli, G.,
Molinuevo, J. L.,
Krahnke, T.,
Strohmaier, C.
Background: Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer’s disease (AD).; Methods: Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24 h rivastigmine patch in patients with AD demonstrating functional and cognitive decline with […]
A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects
Grimaldi, Luigi Maria,
Zappalà, Giuseppe,
Iemolo, Francesco,
Castellano, Anna,
Ruggieri, Stefano,
Bruno, Giuseppe,
Paolillo, Andrea
Despite the fact that multiple sclerosis (MS) and Alzheimer’s disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFNβ1a in subjects affected by mild-to-moderate AD in […]
Robot services for elderly with cognitive impairment: testing usability of graphical user interfaces
Granata, C.,
Pino, M.,
Legouverneur, G.,
Vidal, J. S.,
Bidaud, P.,
Rigaud, A. S.
Background: Socially assistive robotics for elderly care is a growing field. However, although robotics has the potential to support elderly in daily tasks by offering specific services, the development of usable interfaces is still a challenge. Since several factors such as age or disease-related changes in perceptual or cognitive abilities and familiarity with computer technologies […]